Tenuate
(Diethylpropion)PreclinicalSmall molecule
Tenuate is one of 47 small molecule programs targeting Obesity. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Maridebart Cafraglutide
AmgenPhase 3
Retatrutide
Eli LillyPhase 3
NNC0487-0111
Novo NordiskPhase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Berobenatide
PfizerPhase 3
Zenagamtide
Novo NordiskPhase 3
Ribupatide
KKailera
Phase 3
Elecoglipron
AstraZenecaPhase 3
PF-08653944
PfizerPhase 3
Survodutide
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obesity1 trial
Anti-obesity Pharmacotherapy and Inflammation
Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
TENUATE
NDA NDA017669
Jan 1, 1982
TENUATE DOSPAN
NDA NDA012546
Jan 1, 1982
TEPANIL TEN-TAB
NDA NDA017956
Jan 1, 1982
TENUATE
NDA NDA011722
Jan 1, 1982
TENUATE
NDA NDA017668
Jan 1, 1982
TEPANIL
NDA NDA011673
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diethylpropion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]